Last updated on November 2019

Safety Tolerability and Pharmacokinetics of MK-1654 in Infants (MK-1654-002)


Brief description of study

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and incidence of anti-drug antibodies (ADAs) of single ascending doses of MK-1654 in healthy pre-term (born at 29 to 35 weeks gestational age) and full-term (born at >35 weeks gestational age) infants. Key safety and tolerability variables will be reviewed after each panel prior to administering the next-highest dose.

Clinical Study Identifier: NCT03524118

Find a site near you

Start Over